Transaction · 0001193125-26-447899

Vieira Roberto Wandenkolk

Vieira Roberto Wandenkolk, PRES, reported a transaction classified as exercise at CORCEPT THERAPEUTICS INC involving 8333.000000 shares for an estimated $0.00. Reported holdings after the transaction were 125001.000000 shares. The stored filing text includes a detected 10b5-1 reference.

exerciseSEC transaction code MPRES
CORTCORCEPT THERAPEUTICS INC
Trade date
Nov 02, 2026
Filing date
Nov 05, 2026
View on SEC Insider profile
Disclosed value$0Shares × reported price
Shares traded8.33k$0.00 per share
Holdings after125kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

CORT price since this filing

Daily closing prices, with the filing date and available return windows
CORT · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +46.7%1w ago +10.0%1d ago +2.4%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
exercise
Code M
Identifier
0001193125-26-447899
Stock option (right to buy)
Transaction date
Nov 02, 2026
Filed Nov 05, 2026, 12:20 AM · 3d delay
Shares
8,333 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
125,001 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership 10b5-1 Detected
Filing-only score

-20 points

Compact filing score computed from stored Form 4 facts. Version v1.

Low filing signal

This filing has a meaningfully negative filing-only score. It is likely less useful as a positive insider-activity signal.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President, Oncology

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the…

  2. F2

    This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the Reporting Person being appointed an officer of the Issuer, which was in effect at the…

  3. F3

    Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.15 to $81.12 per share. Information on the exact number of shares sold at each sa…

  4. F4

    Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.17 to $82.07 per share. Information on the exact number of shares sold at each sa…

  5. F5

    Shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable…

Original filing · 0001193125-26-447899
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

CORT